Skip to main content
OpenTrials

Clinical trial condition

HER2-positive Early Breast Cancer

Explore clinical trials studying HER2-positive Early Breast Cancer. Study availability and eligibility vary by location and protocol.

7 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

HER2-positive Early Breast Cancer trial results

Recruiting

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

NCT05704829

Conditions
Disease Attributes, HER2-positive Early Breast Cancer, Pathologic Processes, +2 more
Locations
  • Klinikum Mittelbaden, Brustzentrum Baden-Baden, Baden-Wurttemberg, Germany
  • Praxis für Interdisziplinäre Onkologie und Hämatologie (PIO) Freiburg im Breisgau, Baden-Wurttemberg, Germany
  • Universitätsklinikum Tübingen Tübingen, Baden-Wurttemberg, Germany
  • Universitätsklinikum Ulm Ulm, Baden-Wurttemberg, Germany
View all 44 locations
View Trial Details
Completed

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

NCT04024462

Conditions
HER2-positive Early Breast Cancer
Locations
  • Peking University People's Hospital Beijing, China
  • Beijing Cancer Hospital Beijing, China
  • Jilin Cancer Hospital Changchun, China
  • The First Hospital of Jilin University Changchun, China
View all 18 locations
View Trial Details
Completed

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

NCT03674112

Conditions
HER2-positive Early Breast Cancer
Locations
  • Rocky Mountain Cancer Center - Lakewood (West) Lakewood, Colorado, United States
  • Illinois Cancer Care Peoria, Illinois, United States
  • Cancer Center of Kansas Wichita, Kansas, United States
  • Maryland Oncology Hematology Rockville, Maryland, United States
View all 40 locations
View Trial Details
Active, Not Recruiting

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

NCT05113251

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +5 more
Locations
  • Research Site Springdale, Arkansas, United States
  • Research Site Beverly Hills, California, United States
  • Research Site Glendale, California, United States
  • Research Site Los Alamitos, California, United States
View all 145 locations
View Trial Details

Related conditions